Pancragen
Pancreas peptide bioregulator
Pancragen (Pancreas peptide bioregulator) is a longevity & bioregulators research compound. Pancreatic bioregulator — proposed to support pancreatic cell function and carbohydrate/metabolic regulation.
Pancragen quick facts
| Reported research dose | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~30 min |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Pancreas/metabolic bioregulator — short courses. The pancreatic peptide, overlapping heavily with Suprefort. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, fasting insulin and HbA1c — this is one of the few in the set with an obvious number attached. Run it as an experiment you measure, not a protocol you trust.
How Pancragen works
Pancreatic bioregulator — proposed to support pancreatic cell function and carbohydrate/metabolic regulation.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Pancragen
Buy Pancragen at Biolongevity Labs →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Pancragen
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold for pancreatic function and carbohydrate metabolism, and used by people targeting glucose control. This is the arm where self-testing is easiest and most worth doing — fasting glucose and HbA1c are cheap and objective.
🧪 Theoretical / extrapolated
- Lys-Glu-Asp-Trp — a defined tetrapeptide targeting pancreatic tissue, proposed to support beta-cell function.
- The shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
- If the mechanism is real anywhere, this is where it would be provable. A twelve-week HbA1c comparison is a standard, inexpensive trial design used routinely for diabetes drugs. Its absence after decades is the strongest argument against the series as a whole.
How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pancragen actually does
Pancragen is Lys-Glu-Asp-Trp: 4 residues, formula C26H36N6O9, average mass 576.61 Da. It is the most chemically distinctive molecule in the whole Khavinson catalog and nobody writing about it says why, so here are the two features that matter.
It contains the only tryptophan in the set. Tryptophan absorbs ultraviolet light at 280 nm, which means this peptide — unlike Epitalon, Bronchogen, Cardiogen or any of the purely aliphatic and acidic members — can be quantified on a standard reverse-phase HPLC run with a UV detector, with no derivatization and no mass spectrometer. Purity and content of a vial are therefore cheaply checkable here in a way they are not for its siblings. That is a practical fact with a buying consequence and it appears on no vendor page.
The published record is ambiguous about which molecule this is. The group's own 2023 transporter assessment lists it as KEDW-NH2 — the C-terminally amidated form Khavinson 2023 — while the free-acid form is what most sequence listings imply. That single change is not cosmetic. The free acid computes to a net charge of about −1.06 at blood pH with an isoelectric point of 4.18; capping the C-terminus as an amide removes one negative charge and gives about −0.06 at blood pH with an isoelectric point of 6.46. One of those is an anion in plasma and the other is close to neutral, and they differ in mass by 1 Da, which a routine certificate of analysis reporting a rounded figure will not resolve. Near-neutral molecules behave differently at a membrane than anions do, so this is the difference between two mechanistic stories, not a footnote.
What it is proposed to do. The 2021 gene-expression review credits KEDW with stimulating maturation of several human pancreatic cell types and with raising expression of a specific set of developmental transcription factors — PDX1, NGN3, MNX1, PAX6, FOXA2, NKX2-2, NKX6.1, HOXA3 and PAX4 Khavinson 2021. That list is not arbitrary: PDX1 and NKX6.1 are the canonical beta-cell identity factors and NGN3 is the endocrine progenitor switch. The claim being made is therefore a strong one — that a 4-residue peptide re-engages a developmental transcription program in adult pancreas. The same review reports KEDW among the peptides binding fluorescently tagged histones H1, H2B, H3 and H4, which is the proposed route from peptide to promoter, and the structural difficulty of making a peptide that short read a specific DNA sequence is the subject of this group's own motif search Kolchina 2019.
Cell, rodent, human — and where it stops
In cells. Human pancreatic cell cultures, peptide added to the medium, readout by expression of the transcription factors listed above Khavinson 2021. Culture is where every gene-level result for this molecule lives — and the nuclear entry those results presuppose was demonstrated in HeLa cells Fedoreyeva 2011, a cervical carcinoma line, rather than in an islet. Older and closer to the tissue: organotypic culture of pancreatic explants from 3-week-old and 18-month-old rats, with the tetrapeptide at 0.05 ng/mL, reported a stimulating effect against control explants in all groups Zakutskiĭ 2006 — in the matching tissue, with no non-matching tissue reported, which is the arm that would turn the word 'tissue-specific' in that paper's title into an observation.
In animals, and this is the best single study in the entire Khavinson catalog. Old female rhesus monkeys — a non-human primate, not a rat — given the tetrapeptide intramuscularly, once daily, at microgram scale, for 10 days Goncharova 2014. The readout was a glucose challenge rather than a fasting draw. At baseline the old animals showed the pattern you would expect: slower glucose disappearance than young animals, with higher insulin and C-peptide peaks at 5 and 15 minutes — more insulin doing less work, which is insulin resistance written out in numbers. After the 10-day course the glucose disappearance rate rose markedly and the insulin and C-peptide dynamics normalized, and the paper reports the effect partially persisting 3 weeks after the last dose. A primate model, a dynamic test, and a durable effect is a better package than almost anything else on this site's Khavinson pages, and it should be said plainly before the caveats.
The caveats on that study, which are also real. It is a short Russian-language report in Advances in Gerontology, primate group sizes in this kind of work are small, no independent laboratory has repeated it, and the route was intramuscular injection in a restrained animal. It is one study.
In humans: 0 trials. No randomized study, no controlled study, no published series with a glycemic endpoint. The independent systematic review covering this family pooled 24 randomized trials over 2,245 participants, judged risk of bias moderate to high and certainty of evidence low to very low, and has no metabolic arm Alsulaimani 2021.
The obstacles. (1) The gap between a transcription factor and a blood sugar is enormous. Raising PDX1 message in a cultured cell and lowering fasting glucose in a person are separated by protein translation, granule formation, insulin secretion coupled to glucose sensing, hepatic and peripheral insulin sensitivity, and beta-cell mass — and this compound has been measured at one end of that chain and marketed at the other. (2) 4 residues sits outside the di- and tripeptide substrate range the group's own transport work describes for PEPT1, PEPT2, LAT1 and LAT2 Khavinson 2022, and the 2023 scoring of 26 peptides against those carriers was computational docking against all 8,400 possible di- and tripeptides with no cellular uptake measured Khavinson 2023. (3) The amidation ambiguity above means the cell work, the monkey work and the product in a vial may not all be the same molecule. (4) Nothing measures whether the peptide reaches pancreatic tissue in any species; tissue specificity is the premise, not a finding.
What would have to be true, and how you would know it was not
Three predictions, and the second is the one that will make most self-experiments on this compound uninterpretable if it is ignored.
1. Fructosamine is the only glycemic marker whose clock matches the course, and nobody uses it. A course here runs 10 to 20 days. HbA1c reports the previous 2 to 3 months because it tracks the lifespan of a red blood cell, so a 20-day course cannot move it in any interpretable way — this site's own retest interval for HbA1c is every 3 months, and that is the reason. Fructosamine reflects roughly the previous 2 to 3 weeks and this site's retest guidance for it is every 3 to 4 weeks during an active intervention. So the prediction is specific: if this compound does anything to glycemia at the dose and duration people actually use, fructosamine is where it will show and HbA1c is where it cannot. Draw fructosamine at baseline and again 3 weeks after the course ends.
2. Fasting insulin should be read with a paired glucose, or it will mislead. The proposed mechanism is beta-cell maturation, which would raise insulin output. A rising fasting insulin with a falling glucose is the mechanism working; a rising fasting insulin with an unchanged glucose is worsening insulin resistance wearing the same clothes. Both look like ‘insulin went up’. This site's retest window for fasting insulin is 8 to 12 weeks after an intervention, so the draw belongs after the course rather than during it, and it should be paired with the glucose on the same CMP.
3. The prediction that cuts against the product: lipase should not rise, and if it does the course stops. A compound sold on its ability to drive pancreatic transcription programs is being aimed at an organ whose failure mode is autodigestion. There is no evidence this compound causes pancreatitis and no mechanism specifically predicting it — but the endocrine and exocrine pancreas are the same organ, the exocrine half is the half that hurts, and this site already treats lipase as a baseline-then-only-if-symptoms marker for exactly this reason. New upper abdominal pain radiating to the back, with or without vomiting, is a reason to draw lipase and amylase and stop, not a reason to push through a course.
What nobody has tested yet
Four experiments, and the first is embarrassingly cheap.
1. Nobody has published a UV-HPLC assay of a commercial vial. This is the one peptide in the catalog carrying a tryptophan and therefore the one with a built-in 280 nm chromophore. Purity, content and the free-acid-versus-amide question could be settled on equipment in any university teaching lab. As far as any public record shows, 0 vendors publish a chromatogram.
2. Nobody has repeated the monkey experiment’s design in a person, and that is the strangest gap on this page. The primate result was obtained with a glucose challenge and timed insulin and C-peptide sampling Goncharova 2014. Every human self-experiment on this compound measures a fasting number instead. The animal finding is a change in the shape of a response curve, and a fasting draw cannot see a shape. A mixed-meal or oral glucose tolerance test with C-peptide at 0, 30, 60 and 120 minutes is an ordinary outpatient protocol, it is the human analog of the one experiment that produced this compound’s best result, and it has never been run.
3. Nobody has looked for PDX1 in a human sample. The entire transcription-factor claim rests on cultured cells Khavinson 2021. Circulating extracellular vesicles carry tissue-derived RNA and are obtainable from a blood draw; whether beta-cell transcripts in that compartment respond to this peptide is untested, and it is the only realistic route to a human transcriptional readout without a pancreatic biopsy.
4. Nobody has tested it beside a drug that works. The comparison a reader actually needs is against metformin or a GLP-1 receptor agonist, both of which have large randomized trials with hard endpoints. 0 head-to-head studies exist at any level, including in animals, and until one does, the honest framing is that this is an unstudied compound competing with well-studied ones.
Pancragen — its own safety story, not its class's
The class block is generic. Four things here are not.
Hypoglycemia is the one plausible acute harm, and only in combination. If the compound does what it claims, it increases insulin output. In somebody already taking insulin or a sulfonylurea, an addition that increases endogenous insulin is additive by definition. Nobody has studied that combination, which is exactly why it deserves naming rather than assuming: shakiness, sweating and confusion during a course in an insulin-treated person is a glucose reading, not a peptide side effect to tolerate.
Autoimmune diabetes is the population in whom the mechanism cannot work. In type 1 diabetes and in latent autoimmune diabetes of adults, beta cells are being destroyed by the immune system. A peptide proposed to mature beta cells has nothing to act on, and a delay in starting insulin is dangerous in a way no bioregulator course is. C-peptide and insulin antibodies are the 2 tests that separate that group from type 2, and both are ordinary.
The exocrine half. Covered under the predictions above and repeated here because it is the one symptom that should end a course immediately: upper abdominal pain radiating to the back.
What the absence of reported harm means. 0 adverse events are published for this compound because 0 human trials exist to have recorded one. That is a statement about the evidence base, not about the molecule, and the two get confused constantly in this market.
Sources read for this page
- Zakutskiĭ AN, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats. Advances in Gerontology 2006 · PMID 17152728
- Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow) 2011;76(11):1210–1219 · PMID 22117547
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Goncharova ND, Ivanova LG, Oganian TÉ, Vengerin AA, Khavinson VKh. Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys. Advances in Gerontology 2014;27(4):662–667 · PMID 25946840
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Pancragen — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Pancragen — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Pancragen moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Pancragen in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pancragen
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pancragen — frequently asked questions
What is Pancragen?
Pancragen (Pancreas peptide bioregulator) is a longevity & bioregulators research compound. Pancreatic bioregulator — proposed to support pancreatic cell function and carbohydrate/metabolic regulation.
Is the full Pancragen protocol on this page?
The reported research dose is on this page, along with how Pancragen works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Pancragen?
Pancragen has an approximate half-life of ~30 min, which is part of what determines how often it's dosed.
What's the evidence behind Pancragen?
Current evidence level: Russian studies; limited. Pancragen is offered for research purposes only and is not an approved medicine.
Pancragen inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Pancragen is used for
Pancragen appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Pancragen is the endocrine & reproductive arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.